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Structural systems pharmacology offers a novel way of approaching drug discovery by considering the
global physiological environment of protein targets, and the effects derived of tinkering with them, without
losing the key molecular details. In this article, we review some recent advances in the structural annotation
of cell networks and discuss their potential impact on some of the hottest areas of drug development. In
particular, we analyze recent structure-based strategies to target networks, protein interaction interfaces
and allosteric sites, and how theywill help in the development ofmore potent and specific treatments. Finally,
we propose that mapping genetic variations onto protein networks, beyond the pharmacological targets, can
rationalize interindividual variability in drug response, giving valuable hints to advance toward personalized
medicine.Introduction
The acute productivity crisis in pharmaceutical research and
development questions the approaches to drug discovery
used in the past 30 years. Despite the vast amount of target op-
portunities that genomics initiatives have provided, develop-
ment of truly innovative therapies still has a very low probability
of success, and incremental discovery is not profitable anymore
(Pammolli et al., 2011). Indeed, a recent survey of drug ap-
provals in the past decade shows that, in an era dominated by
reductionist strategies, unspecific phenotypic screening has
contributed the most to the discovery of first-in-class medicines,
while target-centered approaches appear more useful only to
develop follow-on products (Swinney and Anthony, 2011). It is
thus paramount to move away from the ‘‘one disease, one
target, one drug’’ paradigm and consider the complexity of hu-
man pathologies from the early stages of the drug development
process.
Successful disease-modifying therapies are those that safely
shift a pathological state back to a healthy one (Baraba´si et al.,
2011; Pujol et al., 2010). However, given the robustness of bio-
logical systems (Kitano, 2004), it is now widely accepted that
an effective perturbation will seldom be specific, as evidenced
by the rather promiscuous pharmacology of approved drugs
(Paolini et al., 2006; Yildirim et al., 2007). Part of this complex
scenario is encircled in phenotypic screens, although these are
not very informative about the underlying molecular events.
Knowledge of such key processes, i.e., the molecular mecha-
nism of action, is crucial to achieve confidence along the drug
discovery pipeline (Cucurull-Sanchez et al., 2012). Accordingly,
there is wide interest in the retrospectivemechanistic elucidation
of phenotypic outcomes (Chan et al., 2010; Iskar et al., 2012;
Laggner et al., 2012), including those of drugs already in themar-
ket (Gregori-Puigjane´ et al., 2012), because a molecular hypoth-674 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righesis often permits rational drug design and facilitates the assess-
ment of safety profiles.
In this regard, the field of systems biology is providing unprec-
edented molecular instruments to model and tinker with biolog-
ical phenomena (Russell and Aloy, 2008). In turn, systems phar-
macology focuses on the representation of mechanisms of
action and has been proposed as an alternative to overcome
most issues in critical steps of the drug discovery pipeline,
from the inception of the target idea through clinical evaluation.
However, much like with systems biology, the hype about this
transversal body of knowledge will have to concretize its appli-
cations. Systemic approaches facilitate the understanding of
how cells work on a large-scale resolution, but it is necessary
to go from the more general description of biological processes,
in terms of pathways and networks, to the detailed molecular
view in order to design chemical compounds able to modulate
the behavior of the system (Aloy and Russell, 2005; Brown and
Okuno, 2012).
The role of high-resolution three-dimensional (3D) structures
of proteins and complexes has been recognized as fundamental
for both systems biology (Aloy andRussell, 2006) and the rational
design of drug molecules (Schneider and Fechner, 2005). Cur-
rent barriers in drug development, however, emphasize the
need to include several other types of experimental data (protein
interaction networks, metabolic networks, gene expression pro-
files, etc.) in a systemic framework (Aloy and Russell, 2006). In
this article, we discuss the importance of retaining structural
details for next-generation drug discovery. In particular, we
analyze the current state of the structural mapping of protein
networks and discuss how a structural systems pharmacology
view can unveil novel classes of targetable entities, suggesting
therapeutic approaches to complex diseases and personalized
medicine.ts reserved
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Just like complex problems often require complex solutions,
complex systems require complex descriptions. Systems
biology provides such descriptions in the form of networks of in-
teracting entities (Baraba´si and Oltvai, 2004) (proteins, small
molecules, DNA elements, etc.) modeling different types of rela-
tionships, from physical protein-protein interactions (PPIs) to
regulatory interactions involving transcription factors, and pro-
tein-ligand interactions involving natural metabolites (Yamada
and Bork, 2009) or drugs (Yildirim et al., 2007). However, these
descriptions often lack themolecular details necessary to under-
stand how the different, yet interrelated, molecular processes
function. This information is only provided by high-resolution
3D structures, and it is key when it comes to the design of chem-
ical means to modulate such complex systems.
Particularly, for PPI networks, several efforts during previous
years have strived to provide a systematic structural annotation
of the nodes in the network (proteins) and the edges connecting
them in order to reveal the molecular details of the interactions.
Nowadays, we can count on a large number of databases that
collect and classify all of the available structural templates of in-
teractions that are present in the Protein Data Bank (PDB) (Ber-
man et al., 2000) both for entire proteins (Bickerton et al., 2011)
and individual domains, including domain-motif interactions
(Stein and Aloy, 2010) (see Stein et al., 2011a and Winter et al.,
2012a, for recent reviews).
Current efforts aim at systematically merging structural data
with experimentally identified PPIs. Yu and coworkers (Wang
et al., 2012c) combined domain-domain structural templates
with a high-confidence human interactome to rationalize the
role of disease mutations and provide hypotheses explaining
their effects at the molecular level. More recently, we built Inter-
actome3D (http://interactome3d.irbbarcelona.org), a resource
for the structural annotation and modeling of PPIs. Through the
integration of interaction data from the main pathway reposi-
tories, we are able to provide structural details at atomic resolu-
tion for over 12,000 PPIs in eight model organisms. In addition,
unlike static databases, Interactome3D also allows biologists to
upload newly discovered interactions and pathways in any spe-
cies, select the best combination of structural templates, and
build 3Dmodels in a fully automatedmanner (Mosca et al., 2013).
These type of resources, which are likely to become a refer-
ence for everyday work in the systems biology community,
need to be constantly updated to take advantage of the growing
volume of structural and interactomics data. Currently, there are
structural data available for about 20%of the over 35,000 human
interactions in Interactome3D (Mosca et al., 2013), in the form of
either an experimental structure (3,181 interactions) or an homol-
ogymodel, and for some pathways we can already get an almost
complete structural overview, as demonstrated, for example, by
the complement cascade pathway (Mosca et al., 2013). It is also
worth noting that, for a large number of interactions (roughly 41%
of the interactome), even if we cannot produce a model for the
complex, we have available structures or models for the two
monomers. This observation, combined with the result of a
recent study showing that90%of protein interfaces have close
structural neighbors, even when the monomers are not related
(Gao and Skolnick, 2010), allows us to foresee the potentials of
computational prediction methods in considerably improvingChemistry & Bthe structural coverage of interactomes. In fact, while the current
perception is that templates are only available for a limited num-
ber of interactions, it has been demonstrated that a template is
available for almost all of the known interactions for which there
is a structure for the two monomers (Kundrotas et al., 2012). We
expect that the structural coverage of interactome networks can
be further increased with large-scale docking experiments
(Mosca et al., 2009) and the structure-based prediction of novel
interactions (Zhang et al., 2012b). However, to fully exploit these
structural data in drug discovery, it is necessary to carefully
assess the impact that the quality of the models might have in
the different pharmacological applications and define strict se-
lection criteria as it has been done for single proteins (Cavasotto
and Phatak, 2009; Skolnick et al., 2013).
The payoff for all of the efforts to structurally annotate PPIs will
certainly be generous, with initial studies demonstrating the po-
tential that such a structural systems biology approach can have
in the understanding of the molecular mechanisms underlying
complex diseases and the corresponding development of treat-
ments. For instance, the addition of structural details to a cancer-
related network and signaling pathways showed that proteins
associated to cancer processes tend to interact with their part-
ners through different binding interfaces (Kar et al., 2009), and
rationalized the effects of drugs targeting specific interactions
in the mitogen-activated protein kinase-signaling pathway
(Kuzu et al., 2012).
In parallel with PPI networks, protein-ligand networks have
also been structurally annotated. The collection of experimental
structures andhomologymodels for the entiremetabolic network
of Thermotoga maritima allowed us to gain evolutionary insights
on the structural composition of the network in terms of folds
and their relationship with basic metabolic functions (Zhang
et al., 2009). At the same time, it demonstrated that the structural
knowledge in the PDB is sufficient for us to start thinking about a
large-scale annotation of the metabolome of entire organisms.
Also drug-target networks have been subject of study. In
particular, the structural annotation of the Mycobacterium
tuberculosis (M.tb) ‘‘drugome’’, i.e., the drug-target network,
was able to connect 123 drugs to more than 1,700 proteins
with structural data, revealing that approximately one third of
the drugs in the network have the potential to be repositioned
to treat tuberculosis and thatmanyM.tb receptorsmay be chem-
ically druggable (Kinnings et al., 2010). This last study shows how
the combination of structures with protein-ligand networks can
aid the discovery and design of new therapeutic opportunities.
We anticipate that, in the next years, these integrated net-
works will become more and more common among biologists
and pharmacologists as an effective way to robustly combine
heterogeneous sources of information, as illustrated by the
structurally annotated interactome of synapses (von Eichborn
et al., 2012). This network, that combines protein structures
and homology models with PPIs and drugs, has shown a good
potential to explain drugs’ side effects by placing drug targets
in their interaction environments, connecting them with biolog-
ical pathways and crosstalks, and enabling structure-based pre-
diction of off-targets.
In addition to helping explain the mechanisms of action
of drugs, and perhaps more importantly, the characterization
ofmore structured networks expands the universe of therapeuticiology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 675
Figure 1. Structural Systems Pharmacology
The structural characterization of cellular networks helps explaining drug mechanisms of action and has expanded the universe of therapeutic strategies,
revealing novel classes of targetable entities better suited to fight complex diseases.
Polypharmacology: rational design in polypharmacology involves the modulation of various proteins to target the network more efficiently. For example, the dual
inhibition of mTOR and PI3K is a promising strategy to treat many cancer types (Fan et al., 2006). It is interesting that these kinases share a considerable degree
of structural similarity in their active site (indicated in magenta), which facilitates a polypharmacology design (Knight et al., 2010).
Targeting PPI interfaces: a drug can alter PPIs by inhibiting them through competitive binding at the interface or by stabilizing them in cases where, for example,
the interaction is compromised by disease-related mutations (Gordo et al., 2008). Several strategies have been used to tinker with interaction interfaces, with
different levels of success. The stabilization of an helix of BCL-2 naturally binding the antiapoptotic protein MCL-1 has shown a potent inhibitory effect
(Schafmeister et al., 2000). Natural partners have also been used as templates to develop small molecules that target the interaction interface by mimicking the
native binding mode (i.e., ABT-737 bound to Bcl-XL; Lee et al., 2007). Targeting interaction hot spots is perhaps the most used strategy to disrupt PPIs, as
(legend continued on next page)
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suited to fight complex diseases.
Targeting the Network
The recognition that a global view is necessary to describe com-
plex diseases suggests that modulating a single target may not
be enough to challenge the system (Hopkins, 2008). Indeed,
the independent knockout of each of the druggable genes in
the mouse genome revealed that a small proportion of proteins
may be of actual therapeutic interest if perturbed individually
(Zambrowicz and Sands, 2003). Accordingly, it has been sug-
gested that even the mild inhibition of multiple nodes can be
more efficient than the complete inhibition of a single target
(Agoston et al., 2005), which has prompted attempts to generate
global blockades of biological processes and pathways by
simultaneously targeting multiple nodes in the underlying
network (Winter et al., 2012b).
In order to detect and rationally combine several key fragile
points, it is necessary to characterize and analyze the disease-
associated protein networks (Kitano, 2007; Yang et al., 2008).
It is known that the topology of such networks alone already pro-
vides valuable guidance in the identification of potential points of
therapeutic intervention (Penrod et al., 2011). In brief, network
pharmacology involves prioritizing those nodes and edges
that, upon selective modulation, will revert the disease network
to a healthy state or lead it to disruption in the case of anti-infec-
tive and antineoplastic therapies. Biological networks display a
number of features that are very attractive for molecular thera-
pies. For instance, they have a few nodes with many connec-
tions, termed hubs, which play an important role in maintaining
network integrity (Baraba´si and Oltvai, 2004). It is interesting
that less connected bridging nodes that link otherwise isolated
subnetworks can also affect the connectivity but are less lethal
than hubs. These nodes, in addition, are independently regu-
lated, suggesting that their role is to connect distinct biological
modules (Hwang et al., 2008). Similarly, nodes that mediate in-
formation flow are less well coexpressed with their neighbors,
meaning that they are also independently controlled (Yu et al.,
2007). These and other metrics capture the biological context
of a protein and, therefore, its relevance for the disease and
eventual reconstitution. Perhaps it is not surprising that success-
ful drug targets, although most of them conceived with little
network awareness, display characteristic network features
(Wang et al., 2012b).
In practice, from a pharmacological perspective, concerted
multitarget perturbations can be either achieved with drug com-
binations or promiscuous agents. The latter compounds have
the advantage that they do not present imbalance in pharmaco-
kinetics and biodistribution, which provides an added market
value (Lu et al., 2012). The quest for these attractive multitarget
medicines is progressively engaging the field of rational drug
design (Wei et al., 2008) and will soon have a major, if not domi-
nant, role in molecular therapies.illustrated in the interaction between eIF4E and 4E-BP1 (Kozakov et al., 2011). Fin
the unbound nor present in the bound forms of the protein but that can be samp
Allostery: PPIs can be also modulated through conformational changes induced in
exists in high-activity octamers and low-activity hexamers, involving dimeric in
oligomeric equilibrium toward the low-activity hexamer without affecting the act
Chemistry & BDespite the appealing possibilities of network pharmacology,
we must accept that conventional target validation experiments,
like genetic deletions, do not mirror the eventual drug action. In
general, a genetic deletion comprises a node removal, whereas
a drug molecule may just ablate some edges or even strengthen
them (Hopkins, 2008). In this regard, the formidable ambition to
find a small molecule modulator for each function of all proteins
(Schreiber, 2005) should provide validation tools that are closer
to reality. To this aim, the use of 3D structures and rational
library design is said to speed the development of chemical
tools up to three to ten times compared to plain high-throughput
screening (Edwards et al., 2009). Moreover, with only a fraction
of the genome considered to be druggable using our current
chemical toolbox (Hopkins and Groom, 2002; Russ and Lampel,
2005), it is clear that the number of possible network-based
interventions is constrained by proteins’ ability to bind ligands.
A good candidate target, besides having a key position in the
network, needs to be amenable to chemical binding. The latter
assessment is usually sustained on 3D models (Surade and
Blundell, 2012) used to delimit regions in the structure that are
deeply related to the pharmacology of proteins. Identifying
and characterizing these regions is fundamental because the
same ligand can be accommodated by proteins with no
apparent structural homology (Durrant et al., 2010), which in
turn is very suggestive for polypharmacology (see Figure 1).
The detection of putative binding pockets is now feasible on a
large scale (Ito et al., 2012; Kufareva et al., 2012) and, in conse-
quence, molecules can be screened against panels that
embrace large protein families (Beuming and Sherman, 2012;
Brylinski and Skolnick, 2010), significant sections of the struc-
tural proteome (Wang et al., 2012a), or even full metabolisms
relevant to drug discovery, as it was done for M.tb (Kinnings
et al., 2010).
In the scenario of a structurally annotated system, it seems
thus possible to predict exhaustive target profiles of drugs
(Xie et al., 2011). This systems-wide target detection problem
is of direct interest to drug polypharmacology and safety, and
it can also guide drug repositioning (Cheng et al., 2012b),
anticipation of adverse effects (Lounkine et al., 2012), and
chemical library design (Workman and Collins, 2010). Structural
annotation efforts are broadening the applicability of structure-
based screening protocols (Taboureau et al., 2012), for
which the only requirement is a structural model. This is very
attractive if we are to continue a network analysis, since unusual
candidate targets, possibly without known ligands, are likely
to emerge. In this line, a suggested roadmap for antimicrobial
hit discovery integrates the network-based identification of
promising metabolic targets with structure-based screening
(Shen et al., 2010). Likewise, compelling candidate target
collections produced through network analysis, such as the
cytostatic target list from a cancer metabolism model (Folger
et al., 2011), could readily undergo structural annotation and
screening.ally, drugs are being developed that target transient cavities neither present in
led by molecular dynamics methods (Eyrisch and Helms, 2007).
distal sites of the protein. For instance, the porphobilinogen synthase naturally
termediate states. A specific allosteric site for the hexamers would draw the
ive site (Lawrence et al., 2008).
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initial steps to detect binding pockets, they can unveil several
binding sites other than the orthosteric site, if any (see Henrich
et al., 2010, for a review). This is also invaluable for network-
based strategies, because different sites in a protein can corre-
spond to distinct features in the network. It is not surprising that
structural elucidation of previously unresolved targets usually in-
spires new mechanistic ideas, sometimes up to the point of a
true revolution in the field, as it is currently the case with G-pro-
tein-coupled receptors (GPCRs) (Mason et al., 2012). In a
broader sense, disposing of several intervention points in a pro-
tein structure allows us to better choose how to modulate its
interplay with the rest of the system.
Another interesting possibility that arises when we consider
the network as the pharmacological target is the ability to affect
undruggable protein nodes indirectly by targeting upstream in-
teractors, which we discuss in detail later in the Allosteric Mod-
ulation section.
PPI Interfaces as Drug Targets
PPIs are very attractive targets since alterations on the edges of
the interactome are the underlying cause in many disorders
(Zanzoni et al., 2009; Zhong et al., 2009), in turn proving their sen-
sibility to elicit distinct phenotypes. In addition, targeting
interactions has certain advantages over more traditional tar-
gets. For instance, blocking an interaction often offers a subtler,
specific form of regulation that can avoid side effects owing to
the total ablation of normal enzyme activity (Russell and Aloy,
2008). However, despite the growing interest of the pharmaceu-
tical companies, the number of interactions that could be tar-
geted is still very limited (Basse et al., 2012), and only now is
research in this field starting to grow in activity (Mullard, 2012).
The structural characteristics of PPI interfaces make them a
difficult target class as they are usually large and flat, and often
lack the cavities present at the surface of small molecule protein
receptors (Fuller et al., 2009). These characteristics were initially
considered as an insurmountable obstacle, but significant
progress has been made in the past years. For instance, novel
experimental assays are under development to assess the
implication of PPIs in disease states and their potential modula-
tion by druglike compounds (Schlecht et al., 2012).
From a more conceptual perspective, binding interfaces are
dynamically adapting, forming on their surface transient cavities
that can accommodate a small molecule. In this regard, compu-
tational methods to explore dynamic conformational changes at
the interaction interface (Eyrisch and Helms, 2007) are funda-
mental, since it has been noted that these transient pockets
are often not present neither in the bound nor in the unbound
conformation of the proteins (Eyrisch and Helms, 2009; Metz
et al., 2012). This highlights the importance of sampling the
structural variability of proteins and complexes in the interac-
tome (Bhardwaj et al., 2011). Indeed, there are ongoing large-
scale efforts to explore the dynamics of proteins, with atomic
resolution, that will allow systematic studies of the cavities pre-
sent in transition states (Stein et al., 2011b). For instance, the
Molecular Dynamics Extended Library (MoDEL) includes trajec-
tories for over 2,000 proteins, which are representative for about
29%of the human proteins and 33%of the therapeutic targets in
DrugBank (Meyer et al., 2010).678 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righIn addition, PPI interfaces are often dominated by hot-spot
residues, which represent the most significant contribution to
the binding energy (Clackson and Wells, 1995). These hot-spots
have a strong relationship with sites having a high propensity for
ligand binding (Zerbe et al., 2012), and they are therefore impor-
tant regions for targeting the PPI. During previous years, several
computational methods have been introduced for the prediction
of PPI hot-spots (see Ferna´ndez-Recio, 2011; Taboureau et al.,
2012, for a review), and most of them base their prediction on
the structure of the interacting proteins. One of these methods,
in particular, combines the sampling of surface flexibility with
computational solvent mapping by small ‘‘probe’’ molecules to
identify druggable sites in PPI interfaces (Zerbe et al., 2012).
The introduction of methods for the prediction of druggable
PPIs is not only providing a guide to identify potential new tar-
gets, but it is also helping in expanding the chemical space of
PPI modulators. Camacho and coworkers have recently devel-
oped a strategy that explores the properties of PPI interfaces
to discover promising starting points for small-molecule design
(Koes and Camacho, 2012). This method, based on the struc-
tural characteristics of PPI interfaces, has been used to create
new large-scale libraries of chemical compounds optimized for
this class of targets (Koes et al., 2012), fulfilling gaps in the chem-
ical space that are hampering the application of more traditional
virtual screening methods to PPIs (Villoutreix et al., 2008).
The search for viable PPI inhibitors is not limited to small mol-
ecules; other classes of compounds are being extensively stud-
ied, including protein interaction mimetics and peptide ligands
(Surade and Blundell, 2012). Several computational methods
have been introduced for the rational design of peptidomimetics
(Floris and Moro, 2012), most of them requiring the 3D structure
of the PPI. While de novo design or geometric methods are still
too computationally expensive, other approaches like those
based on the pharmacophoric characterization of the binding
peptides can be applied on a large scale, suggesting the possi-
bility of a characterization of targetable binding interfaces at the
interactome level. Also on the front of peptide ligands, several
experimental and computational methods have been developed
that use the structure of protein complexes, either by extracting
the natural binding peptides (Bhardwaj et al., 2011; Watt, 2006)
or by using the structural interface on the two partners for
docking screens (Vanhee et al., 2011) (see PPI interfaces in
Figure 1).
Finally, it is worth stressing that PPI modulation not only refers
to the disruption of an interaction but also includes its stabiliza-
tion (Thiel et al., 2012). Even if, at themoment, themolecules able
to act as interaction stabilizers reduce to few anecdotal exam-
ples, some of them are already undergoing clinical studies (Thiel
et al., 2012), and a study of Klebe and coworkers (Block et al.,
2007) suggested that there is large space for the design of this
type of molecules. To this aim, virtual screening based on the
interface structure has already been used for the rational
design of PPI stabilizers (Jiang et al., 2009b), particularly in the
presence of disruptive disease-causing mutations (Gordo
et al., 2008; Ray et al., 2005). These last applications are impor-
tant as the emerging structural maps of the interactome are
enabling the systematic mapping of human disease-related
mutations and the rationalization of their mechanism of action
(Mosca et al., 2013; Wang et al., 2012c) through the discoveryts reserved
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(Zhong et al., 2009).
It is not clear which approach to design PPI modulators will be
themost effective in the future, but certainly we need to abandon
previous preconception regardingwhat is a ‘‘drug-like’’ molecule
(Lipinski et al., 2001) and use the knowledge of successful cases
to better rationalize the chemical space (Sperandio et al., 2010).
To this aim, it will be fundamental to enlarge the data accumu-
lated in databases like TIMBAL (Higueruelo et al., 2009), contain-
ing all known small molecules inhibiting multiprotein complexes,
or 2P2I (Basse et al., 2012), which collects structures of protein-
protein complexes together with their inhibitors. In particular, the
latter contains data from a thorough structural analysis of known
druggable PPI interfaces that will allow a better understanding of
what makes an interface druggable, guiding the hunt for new PPI
targets in the structural interactome.
Allosteric Modulation
Despite the remarkable advances highlighted, it is evident that
finding ligands to target PPI interfaces remains a difficult task.
Nature has evolved several handy tricks to circumvent this diffi-
culty, mainly through allosteric mechanisms. The allosteric effect
occurs when binding at one site of a protein modifies a feature at
another distant site, usually throughout the stabilization of a
particular conformational state (see Figure 1). For instance, we
know that galactose facilitates the formation of a stable Gal3p-
Gal80p complex, which in turn promotes galactose catabolism
in yeast (Jiang et al., 2009a). The peculiarities of allosteric mech-
anisms have been widely studied, and it is now accepted that
small molecules can be engineered to inhibit or stabilize PPI in-
terfaces through distal binding (Arkin and Wells, 2004; Weinkam
et al., 2012). Paclitaxel, for instance, binds to a hydrophobic
pocket of polymerized tubulin located on the b subunit, possibly
strengthening the lateral contacts with neighboring subunits
in the microtubule filament (Lo¨we et al., 2001). A canonical
therapeutic example of allosterically modified PPIs comprises
GPCR regulators, which activate or inhibit downstream signals
by altering the interactions that occur between GPCRs and their
effector proteins (Conn et al., 2009).
A suggestive observation is that even subtle conformational
changes can influence one allosterically induced mechanism
over another. For example, a molecular dynamics study recently
showed that two distinct, yet interrelated, allosteric events
mediate both pro- and anticoagulant activities of the thrombin-
thrombomodulin complex (Gasper et al., 2012). In effect,
allosteric signals may also propagate solely by altering protein
dynamics, without detectable conformational changes (Tsai
et al., 2008). This fine, selective behavior is very attractive for
the drug discovery enterprise because it does not lead to a
completely inoperative target, as in the case of classical orthos-
teric binding. Accordingly, the recently solved structure of the
tetrameric protein kinase A holoenzyme highlights that mecha-
nisms controlling multidomain or multiprotein complexes cannot
be completely unraveled without structural models that contain
all of the components, including associated regulatory proteins
(Zhang et al., 2012a). This is in agreement with the finding that
even scaffolding proteins actively participate in regulation
(Good et al., 2009) and emphasizes the need for full assemblies
at structural resolution to design allosteric interventions.Chemistry & BBesides distant ligand binding, Nature uses post-translational
modifications (PTMs) to regulate complexes (Thompson et al.,
2012). PTMs are well known to promote or inhibit binding at
many PPI interfaces, but they can also achieve so by allosteric
means (Deribe et al., 2010). The current perception is that
PTMs can be combined in many ways to spell an immense
collection of codes (Nussinov et al., 2012). However, since
PTMs require selective covalent binding, it is even more chal-
lenging to design synthetic molecules to mimic their effect. A
successful case includes compounds that covalently bind
Keach-like ECH-associated protein 1 (KEAP1) and stabilize the
NF-E2-related factor 2-KEAP1 complex (Ahn et al., 2010). While
challenging to mimic, the richness in PTM allostery underlines
the fact that, in many proteins, local perturbations, with distinct
physicochemical properties, can elicit singular allosteric effects.
This is in agreement with the notion that diverse ligands can
shape a protein differently, even when they accommodate in
the same pocket (Ma et al., 2002). Hence, it appears that a com-
parable richness inmodulation to that of PTMs can be achieved if
protein structure and binding are examined with enough insis-
tency. The BCR-ABL oncogene is a good example for this, since
it currently disposes of a diverse toolbox of ATP-binding site
competitors and allosteric inhibitors (Hantschel et al., 2012).
The extensive use of allostery in biological processes sug-
gests therapeutic strategies beyond the classic orthosteric sites.
It is important to note that allosteric sites tend to be under lower
conservation pressure than their orthosteric counterparts, which
facilitates the design of more specific, safer drugs. There is good
chance that allosteric sites can be found in many proteins, as
numerous cryptic sites may be revealed (Bowman and Geissler,
2012), but further research is needed if these are to be detected
as comprehensively and precisely as orthosteric sites. Only
recently, the first resource of allosteric cases has been published
(Huang et al., 2011).
Although allosteric drug design is gaining momentum, little
is known about allosteric mechanisms involving cellular path-
ways. Most efforts are devoted to individual proteins or com-
plexes; yet, the allosteric effect is not confined to individual
systems and travels across signal transduction pathways (Ma
and Nussinov, 2009). With the now available systems and struc-
tural data, we might have reached the point in which concerted
allosteric effects can be addressed at the level of pathways
(Antal et al., 2009). Indeed, it has been argued that our current
conception of allosteric drugs, which are designed to directly
target a specific misfunctional protein, could be regarded as a
particular case of allostery across cellular networks (Nussinov
et al., 2011). Integration of cellular networks with structurally
derived conformational ensembles allows, in principle, to aim
at proteins other than the obvious targets in the pathway. Such
a mechanism would produce allosteric effects over great
distances, via several proteins, to ultimately reach a disease-
relevant point. The critical requirement for the realization of
this concept is the construction of structural cellular pathways
and large multimolecular assemblies, followed by the examina-
tion of molecular details to find the appropriate allosteric sites
(Nussinov et al., 2011). While the application of this approach
remains largely academic, we believe that recent progress in un-
derstanding conformational dynamics and redistribution
following an allosteric event (Lee et al., 2011), plus the availabilityiology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 679
Figure 2. Toward Personalized Medicine
Genetic variations in pharmacological targets can have an important effect through the direct or indirect perturbation of the drug-binding cavity, leading to an
alteration in the response to the treatment. In addition, they can also have an impact on the topology of cellular networks, altering the expression levels of certain
nodes or disrupting/stabilizing the interactions, which may silence or enhance the propagation of therapeutic and undesired molecular perturbations.
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Reviewof structurally annotated networks, will finally pave the way for
inducing distinct network states (Ideker and Krogan, 2012) with
indirect modulators. In amore general framework, the incorpora-
tion of time-series data would also refine our understanding
of the dynamic changes that lead from one biological stage to
another and suggest potential points to interfere with disease
progression.
Toward Personalized Medicine
On top of the systemic complexity, novel therapies will have to
consider interindividual variability in drug response. Not all
patients experience the same beneficial drug effects, nor are
they equally susceptible to adverse events. It has been sug-
gested that genetic diversity is one of the major contributors
to inconsistent drug response (Wilke and Dolan, 2011). The cur-
rent estimate is that each of us differs from the reference human
genome at 10,000–11,000 nonsynonymous sites (The 1000
Genomes Project Consortium, 2010). The emerging field of
pharmacogenomics is committed to relating this genetic vari-
ability to individual drug response. Early efforts in pharmacoge-
nomics have focused on candidate genes encoding common
drug effector proteins. The U.S. Food and Drug Administration
has thus far required revisions to the labels of several dozen
medicines to include pharmacogenomics information (Crews
et al., 2012). Moreover, rare variants have been found abundant
in drug target genes (Nelson et al., 2012), and there is mounting
evidence that many critical variants correspond to genes
devoted to drug metabolism and distribution (Yiannakopoulou,
2012). The immediate question is, therefore, to what extent do680 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righgenetic variants have an impact on the physical interaction
between a drug and its transporters, metabolizing enzymes
and targets. For this, it is important to understand how muta-
tions translate into the 3D structure of gene products and the
consequences for drug binding. A natural variant in the target
protein may induce a direct or indirect perturbation of the bind-
ing cavity, leading to an alteration in the response to the treat-
ment (Figure 2). Resources that map mutations on drug targets
(Yang et al., 2011) and drug-metabolizing enzymes (Preissner
et al., 2010), or in a proteome-wide scale (Luu et al., 2012), are
now emerging to incorporate this information in the rational
design of personalized therapies.
There are already several successful stories that highlight the
role of structural insights in advancing toward personalized
medicine (see Lahti et al., 2012, for an exhaustive review).
Two canonical examples include the imatinib-resistant ABL
T315I gatekeeper mutation in BCR-ABL positive chronic
myeloid leukemia, and the I359L mutation in the promiscuous
CYP2C9 drug-metabolizing enzyme. Examination of the crystal
structure of the ABL T315I mutant compared with that of the
wild-type kinase revealed that the replacement with isoleucine
blocked binding of imatinib in the active site (Zhou et al.,
2007), and this has brought about the accommodation of inhib-
itors in alternative pockets (Chan et al., 2011). Sometimes, how-
ever, as in the case of the CYP2C9 I359L mutant, the liable mu-
tation does not sterically hinder drug binding, but the pocket is
modified throughout a long-range perturbation. In effect, the
I359L mutation enlarges the catalytic domain, thereby reducing
the enzymatic activity of CYP2C9 (Sano et al., 2010). It ists reserved
Chemistry & Biology
Reviewinteresting that CYP2C9 genotyping, which accounts for this
altered metabolism, has culminated in improved warfarin dosing
in the clinics (Tan et al., 2010).
Genetic variation may also cause changes in the topology of
cellular networks, for instance, by changing protein expression,
which mostly affects nodes, or by disrupting or stabilizing PPIs
that correspond to edges in a protein interaction network.
Even if these variants do not directly affect drug binding, they
may silence or enhance the propagation of molecular perturba-
tions (Figure 2). For instance, a recent work investigating the
structure of the Ras–c-Raf complex, and the downstream activa-
tion of ERK, suggested that integrating the analysis of protein
structure with pathway kinetics can serve as ameans to interpret
the physiological impact of missense mutations (Kiel and
Serrano, 2009). This was later confirmed in other relevant exam-
ples, with a simplified mathematical formulation that proved the
importance of protein structures in system dynamics modeling
(Cheng et al., 2012a). However, to gain a systemic view of drug
action, more agnostic approaches, such as genome-wide asso-
ciation studies and whole-genome sequencing (Crews et al.,
2012), are required to relate individual genetic variations to their
structural context in the more general framework of the human
interactome, in a way similar to what was done for disease-
related mutations (Wang et al., 2012c). The Pharmacogenomics
Knowledgebase (PharmGKB; http://www.pharmgkb.org/) col-
lects and disseminates clinical evidence of variant-drug associ-
ations and is now incorporating curated knowledge obtained
from genome sequencing. As of December 2012, PharmGKB
contained 401 drugs with genetic information and 749 genes
with single-nucleotide polymorphisms of pharmacogenomic
relevance. Of these, 47 were particularly well documented with
concise summaries of important variants, haplotypes, and
drugs. Resources like this one will facilitate the depiction of indi-
vidual genetic data on interaction networks for the better contex-
tualization of drug molecules in complex systems, which should
take personalized medicine far beyond the handful of individual
genes that are currently being genotyped.Concluding Remarks
The inherent limitations of the reductionist approaches that
have prevailed in drug discovery in the past 30 years have high-
lighted the need of considering the complexity of physiological
responses to treatments at very early stages of the drug devel-
opment process. Systems pharmacology profits from the
description of complex biological processes, involving high
levels of molecular interconnectivity, to suggest novel thera-
peutic strategies. In particular, the structural annotation of cell
networks has already revealed new classes of targets, better
suited to address the complexity of biological systems, that
should result in more potent, specific, and personalized treat-
ments, ultimately reducing the attrition rates observed in clinical
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